ABSTRACT
Objetivo Evaluar la efectividad y seguridad del tratamiento con 5-azacitidina en síndrome mielodisplásico. Métodos Revisión de historias clínicas de pacientes que recibieron 5-azacitidina 75mg/m2 subcutánea durante 7 días, cada 28 días en 12 ciclos. Se valoró la respuesta objetiva, mejoría clínica y tiempo hasta la progresión de la enfermedad. Se recogieron las reacciones adversas descritas en la historia clínica. Resultados Seis pacientes fueron candidatos a tratamiento con 5-azacitidina. Tres casos fueron evaluables tras el período considerado. La mayoría permanecieron en respuesta parcial o mejor al finalizar el estudio, dejando de precisar transfusiones. En una paciente se retrasó la progresión a leucemia.Conclusiones5-Azacitidina podría considerarse un fármaco relativamente efectivo y seguro, pudiendo haber contribuido al control de citopenias periféricas, a mejorar la calidad de vida y a retrasar la progresión a leucemia. Serían necesarios estudios con mayor número de pacientes que corroborasen estos resultados (AU)
Objective To assess the effectiveness and safety of using 5-azacitidine to treat myelodysplastic syndromes. Methods Review of medical records of patients who received 5-azacitidine 75mg/m2 subcutaneously for during 7 days every 28 days in twelve cycles as compassionate use. We evaluated the objective response, clinical improvement and time to disease progression. We recorded adverse reactions described in the medical history. Results Six patients were candidates for treatment with 5-azacitidine. Three cases were evaluated over the study period. Most remained in partial response or better after the study, and no longer needed transfusions. In one patient, the treatment appeared to delay progression to leukaemia.Conclusions5-Azacitidine might be considered an effective and relatively safe drug, and may have contributed to controlling peripheral cytopenias, improving the quality of life and delaying progression to leukaemia. Additional studies with more patients are needed to support these results (AU)
Subject(s)
Humans , Male , Female , Middle Aged , Aged , Antimetabolites/therapeutic use , Azacitidine/therapeutic use , Myelodysplastic Syndromes , Anemia, Refractory, with Excess of Blasts/drug therapy , Anemia, Refractory, with Excess of Blasts/therapy , Combined Modality Therapy , Disease Progression , Drug Eruptions , Drug Evaluation , Medical Records , Platelet Transfusion , Quality of Life , Recombinant Proteins , Retrospective StudiesABSTRACT
OBJECTIVE: To assess the effectiveness and safety of using 5-azacitidine to treat myelodysplastic syndromes. METHODS: Review of medical records of patients who received 5-azacitidine 75mg/m(2) subcutaneously for during 7 days every 28 days in twelve cycles as compassionate use. We evaluated the objective response, clinical improvement and time to disease progression. We recorded adverse reactions described in the medical history. RESULTS: Six patients were candidates for treatment with 5-azacitidine. Three cases were evaluated over the study period. Most remained in partial response or better after the study, and no longer needed transfusions. In one patient, the treatment appeared to delay progression to leukaemia. CONCLUSIONS: 5-Azacitidine might be considered an effective and relatively safe drug, and may have contributed to controlling peripheral cytopenias, improving the quality of life and delaying progression to leukaemia. Additional studies with more patients are needed to support these results.
Subject(s)
Antimetabolites/therapeutic use , Azacitidine/therapeutic use , Myelodysplastic Syndromes/drug therapy , Aged , Anemia, Refractory, with Excess of Blasts/drug therapy , Anemia, Refractory, with Excess of Blasts/therapy , Antimetabolites/adverse effects , Azacitidine/adverse effects , Combined Modality Therapy , Compassionate Use Trials , Diarrhea/chemically induced , Disease Progression , Drug Eruptions/etiology , Drug Evaluation , Female , Filgrastim , Granulocyte Colony-Stimulating Factor/therapeutic use , Humans , Male , Medical Records , Middle Aged , Platelet Transfusion , Quality of Life , Recombinant Proteins , Retrospective StudiesABSTRACT
Objetivo: Identificar los distintos tipos de error de prescripción de citostáticos en pacientes oncohematológicos adultos y pediátricos de nuestro hospital y proponer estrategias de mejora. Métodos: Estudio observacional longitudinal prospectivo en el que se validaron las prescripciones médicas de antineoplásicos procedentes de Hematología y Oncohematología Pediátrica durante 15 me ses. Se clasificaron los tipos de error atendiendo a la terminología y taxonomía publicadas por Otero et al en el documento "Errores de medicación: estandarización de la terminología y clasificación", recogiéndose 11 variables. Entre otros parámetros se determinaron: porcentaje de error global, por tipo de prescripción y servicios, así como de intervención farmacéutica y grado de aceptación. Resultados: Se detectaron un total de 92 errores correspondientes al 1,4% del total de prescripciones, y los de mayor frecuencia fueron: dosificación incorrecta (28,2%), duración incorrecta (21,7%) y volumen y/o vehículo inadecuados (16,3%). Además se detectó una orden de tratamiento de un paciente pediátrico alérgico al citostático prescrito. El 81,8% de órdenes con error se prescribieron de forma manual. En Hematología se obtuvo un 0,9% de error y en Oncohematología Pediátrica un 3,5%. Tanto el índice de intervención farmacéutica como su grado aceptación fueron del 100% (AU)
Objective: To identify the different types of cytostatic prescription errors in adult and paediatric oncohematological patients in our hospital and to propose strategies for improvement. Methods: Longitudinal, prospective, observational study in which prescriptions for antineoplastics from the haematology and paediatric oncohaematology departments were validated over a 15-monthperiod. The types of error were classified in accordance with the terminology and taxonomy published by Otero and cols in the document Medication errors: standardisation of terminology and classification. Eleven variables were recorded. Amongst other parameters, the following were determined: percentage of overall error, percentage of error in type of prescription, percentage of service error, percentage of pharmaceutical intervention and level of acceptance. Results: A total of 92 errors were recorded which corresponded to1.4% of the total prescriptions. The most significant errors were: incorrect dose (28.2%), incorrect duration (21.7%), incorrect volume and/or inadequate vehicle (16.3%), and in one case a prescription was made up where the patient was allergic to the specific cytostatic drug prescribed. 81.8% of prescription errors were made manually. In the haematology department a 0.9% error was recorded, as was a3.5% error in paediatric oncohaematology. Both the rate of pharmaceutical intervention and its level of acceptance were 100% (AU)
Subject(s)
Humans , Medical Errors/statistics & numerical data , Drug Prescriptions/statistics & numerical data , Pharmaceutical Services , Medication Errors/statistics & numerical data , Antineoplastic Agents/administration & dosage , Hematologic Neoplasms/drug therapy , Quality Indicators, Health CareABSTRACT
OBJECTIVE: To identify the different types of cytostatic prescription errors in adult and paediatric oncohematological patients in our hospital and to propose strategies for improvement. METHODS: Longitudinal, prospective, observational study in which prescriptions for antineoplastics from the haematology and paediatric oncohaematology departments were validated over a 15-month period. The types of error were classified in accordance with the terminology and taxonomy published by Otero and cols in the document "Medication errors: standardisation of terminology and classification". Eleven variables were recorded. Amongst other parameters, the following were determined: percentage of overall error, percentage of error in type of prescription, percentage of service error, percentage of pharmaceutical intervention and level of acceptance. RESULTS: A total of 92 errors were recorded which corresponded to 1.4% of the total prescriptions. The most significant errors were: incorrect dose (28.2%), incorrect duration (21.7%), incorrect volume and/or inadequate vehicle (16.3%), and in one case a prescription was made up where the patient was allergic to the specific cytostatic drug prescribed. 81.8% of prescription errors were made manually. In the haematology department a 0.9% error was recorded, as was a 3.5% error in paediatric oncohaematology. Both the rate of pharmaceutical intervention and its level of acceptance were 100%.
